[The requirements to clinicopathology about targeted therapy for breast cancer].
作者信息
Jiang Ze-fei, Shen Ge
出版信息
Zhonghua Bing Li Xue Za Zhi. 2007 Jul;36(7):435-7.
PMID:17845752
Abstract
摘要
相似文献
1
[The requirements to clinicopathology about targeted therapy for breast cancer].
Zhonghua Bing Li Xue Za Zhi. 2007 Jul;36(7):435-7.
2
[Significance of HER2 testing in breast cancer].
Zhonghua Bing Li Xue Za Zhi. 2011 Feb;40(2):76-8.
3
Molecular subtype shift in breast cancer upon trastuzumab treatment: a case report.
Pol J Pathol. 2011;62(1):65-8.
4
[Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Internist (Berl). 2006 Nov;47(11):1183-5. doi: 10.1007/s00108-006-1720-x.
5
A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
Breast J. 2011 Jan-Feb;17(1):109-11. doi: 10.1111/j.1524-4741.2010.01034.x. Epub 2010 Dec 6.
6
Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
Ann Oncol. 2010 Jun;21(6):1376-1377. doi: 10.1093/annonc/mdq228. Epub 2010 Apr 29.
7
HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report.
J Neurooncol. 2006 Sep;79(3):289-92. doi: 10.1007/s11060-006-9139-8. Epub 2006 Jul 5.
8
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Oncology (Williston Park). 2018 Jun;32(6):298-302.
9
[Clinical significance and pathological evaluation of neoadjuvant chemotherapy in breast cancer].
Zhonghua Bing Li Xue Za Zhi. 2010 Apr;39(4):218-21.
10
Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
Breast J. 2006 Sep-Oct;12(5):497-8. doi: 10.1111/j.1075-122X.2006.00314.x.
Zotero 插件